Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 16/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | FPR3 | P25089 | 8/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12040473 | 0.86 | FPR2 (0.76) | FPR2ALDH1A1SMN1; SMN2FPR3PKM | |
| SCHEMBL726966 | 0.85 | FPR2 (0.78) | FPR2ALDH1A1SMN1; SMN2FPR3PKM | |
| SCHEMBL727476 | 0.85 | FPR2 (0.77) | FPR2ALDH1A1SMN1; SMN2FPR3PKM | |
| SCHEMBL16008361 | 0.84 | FPR2 (1.00) | FPR2ALDH1A1SMN1; SMN2FPR3 | |
| SCHEMBL2682702 | 0.84 | FPR2 (1.00) | FPR2ALDH1A1SMN1; SMN2FPR3 | |
| SCHEMBL2683879 | 0.84 | FPR2 (1.00) | FPR2ALDH1A1SMN1; SMN2FPR3 | |
| SCHEMBL855215 | 0.84 | FPR2 (1.00) | FPR2ALDH1A1SMN1; SMN2FPR3 | |
| SCHEMBL20013750 | 0.84 | ALDH1A1 (1.00) | FPR2ALDH1A1SMN1; SMN2FPR3PKM | |
| SCHEMBL726819 | 0.84 | FPR2 (1.00) | FPR2ALDH1A1SMN1; SMN2FPR3PKM | |
| SCHEMBL727471 | 0.83 | FPR2 (0.70) | FPR2ALDH1A1SMN1; SMN2FPR3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163502-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | FPR1, FPR2, FPR3 | FPR2 2/4885ALDH1A1 1981/4885SMN1; SMN2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.